ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients

Study limitation reported by the research below: “Treatment selection bias is likely: patients assigned shorter venetoclax durations (7–14 days) had substantially higher early mortality rates, suggesting they were clinically frailer or had higher-risk disease at baseline, which could confound comparisons across duration groups.”

Papers